Hideyoshi Harashima Selected Research

Hideyoshi Harashima Research Topics

Disease

92	Neoplasms (Cancer) 09/2022 - 10/2005
16	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 02/2007
9	Renal Cell Carcinoma (Grawitz Tumor) 05/2022 - 01/2012
7	Urinary Bladder Neoplasms (Bladder Cancer) 12/2018 - 03/2009
6	Neoplasm Metastasis (Metastasis) 05/2022 - 09/2013
6	Body Weight (Weight, Body) 10/2021 - 08/2011
5	Obesity 10/2021 - 10/2012
5	Type 2 Diabetes Mellitus (MODY) 03/2014 - 12/2003
4	Bites and Stings (Sting) 01/2021 - 06/2014
4	Infections 01/2021 - 01/2013
4	Brain Diseases (Brain Disorder) 01/2018 - 01/2014
3	Fibrosis (Cirrhosis) 05/2022 - 03/2021
3	Melanoma (Melanoma, Malignant) 01/2021 - 03/2011
3	Insulin Resistance 03/2016 - 06/2015
3	Carcinogenesis 06/2011 - 12/2006
2	COVID-19 01/2022 - 10/2021
2	Cardiomyopathies (Cardiomyopathy) 01/2020 - 10/2018
2	Colitis 12/2018 - 07/2016
2	Lymphoma (Lymphomas) 03/2016 - 02/2015
2	Reperfusion Injury 12/2015 - 09/2015
2	Hypersensitivity (Allergy) 06/2011 - 05/2011
2	Tuberculosis (Tuberculoses) 06/2011 - 05/2011
2	Carcinoma (Carcinomatosis) 06/2011 - 03/2009
2	Genomic Instability 03/2008 - 03/2003
1	Bone Resorption 01/2022
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2022
1	Osteolysis 01/2022
1	Weight Gain 01/2022
1	Heart Failure 01/2022
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022
1	Heart Diseases (Heart Disease) 01/2022

Drug/Important Bio-Agent (IBA)

37	Small Interfering RNA (siRNA)IBA 09/2022 - 05/2009
24	Liposomes (Liposome)IBA 01/2022 - 10/2005
19	LipidsIBA 05/2022 - 10/2007
18	Pharmaceutical PreparationsIBA 01/2022 - 02/2007
18	LigandsIBA 01/2022 - 11/2011
15	Peptides (Polypeptides)IBA 01/2019 - 10/2005
14	Lipid NanoparticlesIBA 01/2022 - 06/2011
11	DNA (Deoxyribonucleic Acid)IBA 09/2022 - 03/2003
10	Proteins (Proteins, Gene)FDA Link 04/2015 - 12/2006
9	Messenger RNA (mRNA)IBA 09/2022 - 12/2003
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 09/2007
8	AntigensIBA 01/2022 - 05/2011
8	Mitochondrial DNA (mtDNA)IBA 01/2021 - 10/2008
6	Nucleic AcidsIBA 01/2022 - 01/2010
5	Therapeutic UsesIBA 05/2022 - 06/2011
5	Matrix Metalloproteinases (MMPs)IBA 12/2016 - 05/2007
5	Tuberculin (PPD)IBA 06/2011 - 10/2007
4	InterferonsIBA 01/2021 - 06/2014
4	RNA (Ribonucleic Acid)IBA 11/2020 - 01/2010
4	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2020 - 05/2009
4	octaarginineIBA 11/2019 - 03/2009
4	Hyaluronic Acid (Hyaluronan)IBA 10/2019 - 06/2015
4	CytokinesIBA 11/2017 - 05/2011
4	Insulin (Novolin)FDA Link 03/2016 - 12/2006
4	YSK05IBA 10/2015 - 06/2013
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020 - 12/2016
3	Vitamin E FDA LinkGeneric 01/2020 - 02/2015
3	Cell-Penetrating PeptidesIBA 01/2017 - 08/2012
3	bis(3',5')-cyclic diguanylic acidIBA 12/2016 - 06/2014
3	Blood Glucose (Blood Sugar)IBA 01/2016 - 03/2014
3	Interferon Type IIBA 10/2015 - 06/2014
3	Nucleotide AptamersIBA 08/2014 - 01/2012
3	Cell Wall SkeletonIBA 02/2014 - 06/2011
3	liposomal doxorubicin (Doxil)FDA Link 07/2013 - 02/2007
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 06/2014
2	VaccinesIBA 01/2022 - 01/2022
2	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2022 - 10/2018
2	Sorafenib (BAY 43-9006)FDA Link 10/2021 - 01/2019
2	MidkineIBA 10/2021 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2021 - 11/2020
2	Photosensitizing Agents (Photosensitizers)IBA 01/2020 - 01/2020
2	PorphyrinsIBA 01/2020 - 01/2020
2	OvalbuminIBA 12/2018 - 01/2017
2	Myristic Acid (Tetradecanoic Acid)IBA 12/2018 - 02/2015
2	Dextran SulfateIBA 12/2018 - 07/2016
2	Nanoparticle Drug Delivery SystemIBA 11/2017 - 12/2016
2	coenzyme Q10 (CoQ10)IBA 01/2017 - 09/2015
2	cyclic arginine-glycine-aspartic acid peptideIBA 01/2016 - 09/2015
2	Triglycerides (Triacylglycerol)IBA 01/2016 - 03/2014
2	Glucose (Dextrose)FDA LinkGeneric 06/2015 - 09/2013
2	Biomarkers (Surrogate Marker)IBA 08/2014 - 01/2012
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2014 - 02/2007
2	LeptinIBA 10/2013 - 03/2013
2	Matrix Metalloproteinase 14 (MT1-MMP)IBA 09/2007 - 05/2007
1	BiglycanIBA 05/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Annexin A1IBA 01/2022
1	Toll-Like Receptor 3IBA 01/2022

Therapy/Procedure

43	Therapeutics 05/2022 - 10/2005
21	Immunotherapy 01/2022 - 03/2009
5	Transplantation 01/2022 - 09/2013
3	Photochemotherapy (Photodynamic Therapy) 01/2020 - 08/2008
3	Intravenous Administration 01/2020 - 10/2007
3	Drug Therapy (Chemotherapy) 02/2015 - 01/2014
2	Injections 01/2022 - 01/2014
2	Cell Transplantation 01/2022 - 01/2020
2	Lab-On-A-Chip Devices 10/2021 - 01/2017
2	Lasers (Laser) 01/2017 - 03/2009
1	Arthroplasty 01/2022